Stock Report

Kilitch Drugs' PAT rises by 18% YoY to 10.30 crore in H1 FY26

Posted On : 2025-11-15 09:45:56( TIMEZONE : IST )

Kilitch Drugs Limited (BSE - 524500), a leading pharmaceutical company specializing in high-quality parenterals, oral solids and effervescents, announced its unaudited financial results for the half year ended September 30, 2025.

The company reported a Profit After Tax of 710.30 crore in H1 FY26, an 18.1% increase compared to %8.72 crore in H1 FY25. The growth in profitability was supported by improved operational efficiencies, better product mix and consistent demand across key markets.

Total income for the period stood at 7101.28 crore, registering a 14.23% YoY growth from %88.66 crore in H1 FY25. The company continued to strengthen its presence in domestic and international markets, driven by sustained orders for its parenteral range and increasing traction in oral solids and effervescent formulations.

Commenting on the company's Q2FY26 performance, Mr. Mukund Mehta, Chairman and Managing Director, Kilitch Drugs Limited, said, "Our HIFY26 results reflect steady and broad-based growth across our key markets and product segments. The continued demand for our effervescent, injectable formulation including oral solid dosage formulations, coupled with operational efficiency, has supported our profitability. We remain committed to sustainable growth, and long-term value creation for our stakeholders.

With a healthy order pipeline and steady demand outlook, the company expects business momentum to remain positive in the second half of FY26.

During the quarter ended 30 September 2025, the Company successfully completed a rights issue of 13,98,463 fully paid-up equity shares of face value %10 each, issued at %357 per share (including a premium of %347). The issue aggregated to 4992.51 lakh and was primarily undertaken to fund the capital expenditure for its upcoming Greenfield Project at Pen. These equity shares were allotted on 25 August 2025. This infusion strengthens the company's balance sheet and supports its long-term expansion plans.

Shares of Kilitch Drugs (India) Limited was last trading in BSE at Rs. 359.50 as compared to the previous close of Rs. 368.10. The total number of shares traded during the day was 1333 in over 59 trades.

The stock hit an intraday high of Rs. 375.90 and intraday low of 355.00. The net turnover during the day was Rs. 486010.00.